Ganesan Vaidyanathan, PhD

Professor in Radiology
Member of the Duke Cancer Institute
Address: 161C Bryan Res Bldg
Durham, NC 27710
Phone: (919) 684-7811

Research Interests

Dr. Vaidyanathan is a professor in the Department of Radiology.  He is a member of the Nuclear Medicine track of the Medical Physics Graduate Program.  His research involves development of radiopharmaceuticals especially for oncologic applications.  Some of the projects he is involved in are given below.

I.          New methods of radiohalogenating antibodies and its variants 

a) Development of newer residualizing agents for the radiohalogenation of internalizing monoclonal antibodies.

b)  Development of fluorine-18 labeled residualizing agents for labeling nanobodies.

c) Pre-targeting approach via bioorthogonal chemistry for in vivo labeling of antibodies and nanobodies with 18F and 211At.

d)  Methods to label antibodies pre-conjugated with a prosthetic group of the tin precursor of residualizing agents.

e) Multimodal prosthetic groups for labeling antibodies and peptides with multiple radioisotopes.

II.         MIBG Analogs for PET imaging

Radioiodinated MIBG is used in the diagnosis of the pathophysiology of the heart as well as neuroendocrine tumors such as neuroblastoma (NB).  Design and development of newer fluorine-18 labeled MIBG analogues useful in the PET imaging of NB as well as that of myocardial diseases.

III. Noninvasive Imaging of Alkylguanine-DNA alkyltransferase (AGT) 

AGT is a DNA repair protein and is primarily responsible for drug resistance in alkylator chemotherapy. An inverse correlation has been established between the tumor AGT content and the therapeutic outcome. The amount of AGT varies from tumor to tumor and within a group of patients of similar cancer. Thus, it is important to quantify tumor AGT of individual patients before administering alkylator chemotherapy. Our goal is to develop radiolabeled agents with which AGT can be quantified in a noninvasive manner by PET or SPECT imaging. 

IV. PSMA targeting for prostate cancer therapy 

Development of At-211 labeled urea-based inhibitor of Prostate-specific membrane antigen.


Feng, Yutian, et al. “Evaluation of an 131I-labeled HER2-specific single domain antibody fragment for the radiopharmaceutical therapy of HER2-expressing cancers.Sci Rep, vol. 12, no. 1, Feb. 2022, p. 3020. Pubmed, doi:10.1038/s41598-022-07006-9.

Mease, Ronnie C., et al. “An Improved 211At-Labeled Agent for PSMA-Targeted α-Therapy.J Nucl Med, vol. 63, no. 2, Feb. 2022, pp. 259–67. Pubmed, doi:10.2967/jnumed.121.262098.

Zhou, Zhengyuan, et al. “Site-Specific and Residualizing Linker for 18F Labeling with Enhanced Renal Clearance: Application to an Anti-HER2 Single-Domain Antibody Fragment.J Nucl Med, vol. 62, no. 11, Nov. 2021, pp. 1624–30. Pubmed, doi:10.2967/jnumed.120.261446.

Zhou, Zhengyuan, et al. “Labeling single domain antibody fragments with 18F using a novel residualizing prosthetic agent - N-succinimidyl 3-(1-(2-(2-(2-(2-[18F]fluoroethoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)-5-(guanidinomethyl)benzoate.Nucl Med Biol, vol. 100–101, Sept. 2021, pp. 24–35. Pubmed, doi:10.1016/j.nucmedbio.2021.06.002.

Feng, Yutian, et al. “Therapeutic efficacy of single-dose iso-[211At]SAGMB-anti-HER2 sdAb in mice with subcutaneous HER2-expressing breast carcinoma xenografts.” Journal of Nuclear Medicine, vol. 62, 2021.

Vaidyanathan, Ganesan, et al. “Synthesis and preliminary evaluation of 211At-labeled inhibitors of prostate-specific membrane antigen for targeted alpha particle therapy of prostate cancer.Nucl Med Biol, vol. 94–95, Mar. 2021, pp. 67–80. Pubmed, doi:10.1016/j.nucmedbio.2021.01.002.

Feng, Yutian, et al. “Site-specific radioiodination of an anti-HER2 single domain antibody fragment with a residualizing prosthetic agent.Nucl Med Biol, vol. 92, Jan. 2021, pp. 171–83. Pubmed, doi:10.1016/j.nucmedbio.2020.05.002.

Liu, Yang, et al. “Gold Nanostars: A Novel Platform for Developing 211At-Labeled Agents for Targeted Alpha-Particle Therapy.Int J Nanomedicine, vol. 16, 2021, pp. 7297–305. Pubmed, doi:10.2147/IJN.S327577.